Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)

BACKGROUND: Immune checkpoint inhibitors (ICIs) are currently the standard of care for metastatic urothelial cancer (mUC) after the failure of previous platinum-based chemotherapy. The choice of further therapy after ICI progression is a new challenge, and scarce data support it. We aimed to examine...

Descripción completa

Detalles Bibliográficos
Autores principales: Bersanelli, Melissa, Buti, Sebastiano, Cortellini, Alessio, Bandini, Marco, Banna, Giuseppe Luigi, Pederzoli, Filippo, Farè, Elena, Raggi, Daniele, Giannatempo, Patrizia, De Giorgi, Ugo, Basso, Umberto, Losanno, Tania, Santini, Daniele, Mucciarini, Claudia, Tucci, Marcello, Tambaro, Rosa, Farnesi, Azzurra, Caffo, Orazio, Veccia, Antonello, Naglieri, Emanuele, Briganti, Alberto, Procopio, Giuseppe, Pignata, Sandro, Necchi, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274126/
https://www.ncbi.nlm.nih.gov/pubmed/34290538
http://dx.doi.org/10.1177/11795549211021667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274126/
https://www.ncbi.nlm.nih.gov/pubmed/34290538
http://dx.doi.org/10.1177/11795549211021667

Ejemplares similares